Whole-Body Redox Maps to Guide Prostate Cancer Therapy
Official title: Whole Body Redox Maps for Metastatic Cancer Therapy
Funded at Cold Spring Harbor Laboratory · NIH-11434570 · Data updated 2026-11-12
A new research project will map redox states across the body to understand how prostate cancer and its spread respond to therapy.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Cold Spring Harbor Laboratory NIH-funded |
| Lab location | 1 site (Cold Spring Harbor, United States) |
| Project start | August 6, 2026 |
| Project end | July 31, 2031 |
| Funding year | 2026 |
| Award (this year) | $793,679 |
| NIH project number | 1R01CA315227-01 |
| Project ID | NIH-11434570 on NIH RePORTER |
Who could benefit from this research
✓Could help
Patients with prostate cancer, especially those with metastatic disease, could benefit from future therapies informed by redox-based insights.
✕Less likely to help
Patients without prostate cancer or those not undergoing therapies influenced by redox states may not benefit.
What this research studies
This project aims to visualize how oxidative stress varies in different tissues, including tumors and metastases, using a redox-reporting system in living organisms. By comparing redox maps before and after standard cancer therapies, researchers hope to reveal why some treatments work differently across patients. The work builds on prior findings that certain pro-oxidant approaches can induce cancer cell death while sparing normal tissues. It will use a reporter system that indicates redox stress and a green reference channel to ensure accurate measurements. The goal is to inform personalized treatment approaches based on tissue redox profiles and therapy effects.
Why it matters
Potential benefit: If successful, patients could receive more effective, tailored therapies guided by redox state information.
How similar studies have gone: Previous work showed that redox states can influence treatment responses, and this project extends a validated in vivo redox sensing approach.
Where this research is happening
-
Cold Spring Harbor Laboratory
Cold Spring Harbor, United States Active
Researchers
- Principal investigator: Trotman, Lloyd C — Cold Spring Harbor Laboratory
- Study coordinator: Trotman, Lloyd C
Related research
Other NIH-funded projects on the same topics.
-
Digital activity tracking to understand metastatic breast cancer care
A smartphone-based activity tracking study will help people with metastatic cancer better understand how daily movement relates to health and treatment outcomes.
-
Measuring how cancer patients and doctors talk to each other to improve treatment outcomes
This project uses machine learning to study how patient-provider conversations affect cancer patients’ use of oral therapies and their health results.
-
Symptoms and quality of life during immunotherapy for metastatic cancer
The team will track symptoms and day-to-day quality of life in people with metastatic cancer who are receiving immune checkpoint inhibitor treatments.
-
A New Treatment for Metastatic Cancer
This project is exploring a brand-new treatment designed to specifically target and remove metastatic cancer cells in people with advanced cancer.
-
How cancer cells release proteins that help tumors spread
This project is learning how tumor cells send out certain proteins that help cancer move to other parts of the body, with the goal of helping people with metastatic cancer.
-
Making palliative care work better for people with metastatic cancer
This project aims to find what helps specialist palliative care give better support and quality of life for people with metastatic cancer.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.